Reynaldo Dietze

Reynaldo Dietze

Auto-generated profile, based on publicly available information

Reynaldo Dietze

Núcleo de Doenças Infecciosas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Vitória, Brazil

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SHSri Rezeki Hadinegoro
Sri Rezeki Hadinegoro
JAJose Luis Arredondo-García
Jose Luis Arredondo-García
MCMaria Rosario Capeding
Maria Rosario Capeding
CDCarmen Deseda
Carmen Deseda
TCTawee Chotpitayasunondh
Tawee Chotpitayasunondh
MSMelanie Saville
Melanie Saville
A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific and Latin American countries. We report the results of long-term follow-up interim analyses and integrated efficacy analyses.

8 January 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
LVLuis Villar
Luis Villar
GDGustavo Dayan
Gustavo Dayan
JAJosé Luis Arredondo-García
José Luis Arredondo-García
DRDoris Maribel Rivera
Doris Maribel Rivera
RCRivaldo Cunha
Rivaldo Cunha
CGCYD15 Study Group
CYD15 Study Group
In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development.

1 January 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
SDSusan E Dorman
Susan E Dorman
SSSamuel G Schumacher
Samuel G Schumacher
DADavid Alland
David Alland
PNPamela Nabeta
Pamela Nabeta
DADerek T Armstrong
Derek T Armstrong
YXYingda Xie
Yingda Xie
The Xpert MTB/RIF assay is an automated molecular test that has improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is inadequate in patients with paucibacillary disease or HIV. Xpert MTB/RIF Ultra (Xpert Ultra) was developed to overcome this limitation. We compared the diagnostic performance of Xpert Ultra with that of Xpert for detection of tuberculosis and rifampicin resistance. In this prospective, multicentre, diagnostic accuracy study, we recruited adults with pulmonary tuberculosis symptoms presenting at primary health-care centres and hospitals in eight countries (South Africa, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). Participants were allocated to the case detection group if no drugs had been taken for tuberculosis in the past 6 months or to the multidrug-resistance risk group if drugs for tuberculosis had been taken in the past 6 months, but drug resistance was suspected. Demographic information, medical history, chest imaging results, and HIV test results were recorded at enrolment, and each participant gave at least three sputum specimen on 2 separate days. Xpert and Xpert Ultra diagnostic performance in the same sputum specimen was compared with culture tests and drug susceptibility testing as reference standards. The primary objectives were to estimate and compare the sensitivity of Xpert Ultra test with that of Xpert for detection of smear-negative tuberculosis and rifampicin resistance and to estimate and compare Xpert Ultra and Xpert specificities for detection of rifampicin resistance. Study participants in the case detection group were included in all analyses, whereas participants in the multidrug-resistance risk group were only included in analyses of rifampicin-resistance detection. Between Feb 18, and Dec 24, 2016, we enrolled 2368 participants for sputum sampling. 248 participants were excluded from the analysis, and 1753 participants were distributed to the case detection group (n=1439) and the multidrug-resistance risk group (n=314). Sensitivities of Xpert Ultra and Xpert were 63% and 46%, respectively, for the 137 participants with smear-negative and culture-positive sputum (difference of 17%, 95% CI 10 to 24); 90% and 77%, respectively, for the 115 HIV-positive participants with culture-positive sputum (13%, 6·4 to 21); and 88% and 83%, respectively, across all 462 participants with culture-positive sputum (5·4%, 3·3 to 8·0). Specificities of Xpert Ultra and Xpert for case detection were 96% and 98% (-2·7%, -3·9 to -1·7) overall, and 93% and 98% for patients with a history of tuberculosis. Xpert Ultra and Xpert performed similarly in detecting rifampicin resistance. For tuberculosis case detection, sensitivity of Xpert Ultra was superior to that of Xpert in patients with paucibacillary disease and in patients with HIV. However, this increase in sensitivity came at the expense of a decrease in specificity. Government of Netherlands, Government of Australia, Bill & Melinda Gates Foundation, Government of the UK, and the National Institute of Allergy and Infectious Diseases.

21 November 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
SBShibadas Biswal
Shibadas Biswal
HRHumberto Reynales
Humberto Reynales
XSXavier Saez-Llorens
Xavier Saez-Llorens
PLPio Lopez
Pio Lopez
CBCharissa Borja-Tabora
Charissa Borja-Tabora
DWDerek Wallace
Derek Wallace
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.

1 December 2007 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
MPMoises Palaci
Moises Palaci
RDReynaldo Dietze
Reynaldo Dietze
DHDavid Jamil Hadad
David Jamil Hadad
FRFabiola Karla Corrêa Ribeiro
Fabiola Karla Corrêa Ribeiro
RPRenata Lyrio Peres
Renata Lyrio Peres
KEKathleen D. Eisenach
Kathleen D. Eisenach
We examined sputum bacterial loads in adults with newly diagnosed tuberculosis using quantitative culture and time-until-positive (DTP) culture in BACTEC 460. Patients with cavitary disease had higher CFU levels than those without cavities and shorter DTPs. Within radiographic strata of moderately and far advanced tuberculosis, higher CFU counts were associated with cavitary disease.

1 March 2008 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
CPCharles A. Peloquin
Charles A. Peloquin
DHDavid Jamil Hadad
David Jamil Hadad
LMLucilia Pereira Dutra Molino
Lucilia Pereira Dutra Molino
MPMoises Palaci
Moises Palaci
WBW. Henry Boom
W. Henry Boom
JJJohn L. Johnson
John L. Johnson
The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses. Twenty-nine patients with tuberculosis at the University Hospital in Vitória, Brazil, participated. Subjects received multiple doses of one drug (levofloxacin, 1,000 mg daily, or gatifloxacin or moxifloxacin, 400 mg daily) as part of a 7-day study of early bactericidal activity. Serum samples were collected over 24 h after the fifth dose and assayed using validated high-performance liquid chromatography assays. Concentration-time data were analyzed using noncompartmental, compartmental, and population methods. The three drugs were well tolerated. Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 μg/ml; gatifloxacin, 4.75 μg/ml; moxifloxacin, 6.13 μg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h). A one-compartment model, with or without weight as a covariate, adequately described the data. Postmodeling simulations using median population parameter estimates closely approximated the median values from the original data. Area under the concentration-time curve/MIC ratios for free drug were high. All three quinolones showed favorable pharmacokinetic and pharmacodynamic indices, with the most favorable results in this population being seen with levofloxacin at the comparative doses used.